BIONEER CORPORATION

Bioneer Successfully Concludes Participation in MEDLAB Middle East 2025,
the Largest Medical Device Exhibition in the Middle East

Discussed Business Expansion in the Middle East, Africa, South Asia, and Central Asia

BIONEER announced on February 7 that it participated in MEDLAB Middle East 2025 (hereinafter referred to as MEDLAB), held in Dubai from February 3 to 6, where it engaged in multiple business meetings with various partners to boost sales in the Middle East, Africa, and South Asia. Through this exhibition, BIONEER explored opportunities for market expansion, strengthened collaborations with existing distributors, and actively promoted the competitiveness of its next-generation diagnostic solutions to solidify its global presence.

 Now in its 24th year, MEDLAB is the largest international medical device exhibition in the Middle East, attracting over 800 companies from more than 40 countries and more than 20,000 industry professionals. The event serves as a key platform for information exchange within the industry, providing global companies with opportunities to enter new markets and generate business prospects.

During the exhibition, BIONEER held numerous business meetings to discuss potential market entry in Zambia, Côte d'Ivoire, Egypt, Kuwait, Turkey, and other new regions. The company also reinforced partnerships with existing distributors in the Middle East, Africa, and Central Asia, sharing the value of its products, gathering local market insights, and seeking opportunities to increase sales.

BIONEER also met with global partners to expand its participation in international procurement bids, focusing on HIV diagnostic kits, which were the first in Asia to receive Prequalification (PQ) from the World Health Organization (WHO). The discussions emphasized the technological advancements and competitiveness of its HIV viral load (HIV-VL) quantification kit, exploring strategies for market expansion and collaboration, particularly in low- and middle-income countries. The global HIV-infected population is estimated at approximately 39 million, and the HIV diagnostics market continues to grow. Given that only a few companies worldwide have developed WHO PQ-approved HIV quantification kits—an area that requires high technical precision—BIONEER's product garnered significant attention, further driving its global expansion efforts.

The company also introduced solutions to minimize contamination, a common issue in molecular diagnostics, including the AccuLoader™ (sample loading guide) and Premixed reagent kits. These innovations help reduce contamination during testing, improving diagnostic accuracy. The presentation of these solutions received positive feedback from customers, who recognized their practical applications and effectiveness.

Additionally, BIONEER showcased IRON-qPCR™, which has been registered under the EU Medical Device Regulation (MDR). This advanced diagnostic solution can detect up to 40 pathogens within 30 to 40 minutes, enabling symptom-based infectious disease diagnosis. The company also introduced the RFIA kit, which detects tuberculosis (TB) and multidrug-resistant TB, as well as the AMR&ID kit, which identifies seven bloodstream infection (BSI) pathogens and 17 antibiotic resistance genes. Other key products included the CRE kit for detecting carbapenem-resistant Enterobacteriaceae (CRE) and the RV kit, which can detect five major respiratory viruses.

The company highlighted the advantages of rapid point-of-care diagnostics, emphasizing their potential to improve patient treatment outcomes. These presentations attracted significant interest from attendees, leading to active inquiries about the products.

BIONEER representative stated, "We will continue to enhance cooperation with our existing distributors to address gaps in the market while expanding connections with new partners to meet the demand for next-generation diagnostic products. Through MEDLAB Middle East, we aim to further strengthen our global sales strategy."###